Quantitation of the DNA‐dependent protein kinase inhibitor peposertib (M3814) and metabolite in human plasma by LC–MS/MS
Biomedical Chromatography · 2024-12 · 38 (12)
DOI: 10.1002/bmc.6024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 08.10.2024. Verfasst von Susan M Christner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Protein Kinase Inhibitors, Sulfones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: UPMC Hillman Cancer Center's Cancer Pharmacokinetics and Pharmacodynamics Facility, NCI NIH HHS, Merck KGaA.
Abstract (Originalsprache)
The DNA‐dependent protein kinase (DNA‐PK) is an abundant nuclear protein that mediates DNA double‐strand break repair by nonhomologous end joining (NHEJ). As such, DNA‐PK is critical for V(D)J recombination in lymphocytes and for survival in cells exposed to ionizing radiation and clastogens. Peposertib (M3814) is a small molecule DNA‐PK inhibitor currently in preclinical and clinical development for cancer treatment. We have developed a high‐performance liquid chromatography‐mass spectrometry method for quantitating peposertib and its metabolite in 0.1 mL human plasma. After MTBE liquid–liquid extraction, chromatographic separation was achieved with a Phenomenex Synergi polar reverse phase (4 μm, 2 × 50 mm) column and a gradient of 0.1% formic acid in acetonitrile and water over an 8 min run time. Mass spectrometric detection was performed on an ABI SCIEX 4000 with electrospray, positive‐mode ionization. The assay was linear from 10 to 3000 ng/mL for peposertib and 1–300 ng/mL for the metabolite and proved to be both accurate (97.3%–103.7%) and precise (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Jan H Beumer
Förderung
- UPMC Hillman Cancer Center's Cancer Pharmacokinetics and Pharmacodynamics Facility
- NCI NIH HHS
- Merck KGaA
- National Cancer Institute
Zitieren
APA
Christner, S. M., Parise, R. A., Bakkenist, C. J., Davis, S. L., Feng, Y., Synold, T., Gore, S., & Beumer, J. H. (2024). Quantitation of the DNA‐dependent protein kinase inhibitor peposertib (M3814) and metabolite in human plasma by LC–MS/MS. Biomedical Chromatography, 38(12). https://doi.org/10.1002/bmc.6024
Vancouver
Christner SM, Parise RA, Bakkenist CJ, Davis SL, Feng Y, Synold T, et al. Quantitation of the DNA‐dependent protein kinase inhibitor peposertib (M3814) and metabolite in human plasma by LC–MS/MS. Biomedical Chromatography. 2024;38(12). doi:10.1002/bmc.6024
BibTeX
@article{Christner2024,
author = {Christner, Susan M and Parise, Robert A and Bakkenist, Christopher J and Davis, S Lindsey and Feng, Ye and Synold, Timothy and Gore, Steven and Beumer, Jan H},
title = {Quantitation of the DNA‐dependent protein kinase inhibitor peposertib (M3814) and metabolite in human plasma by LC–MS/MS},
journal = {Biomedical Chromatography},
year = {2024},
volume = {38},
number = {12},
doi = {10.1002/bmc.6024}
}
EUVIMED